Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine

被引:42
作者
Kwarcinski, Frank E. [1 ]
Fox, Christel C. [1 ]
Steffey, Michael E. [1 ]
Soellner, Matthew B. [1 ,2 ]
机构
[1] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
TYROSINE KINASES; P-LOOP; PROTEIN-KINASES; CELL-LINES; RESISTANCE; ABL; SELECTIVITY; CONFORMATIONS; COMPLEXES; SUBSTRATE;
D O I
10.1021/cb300337u
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
We have developed the first irreversible inhibitors of wild type c-Src kinase. We demonstrate that our irreversible,inhibitors display improved selectivity,potency and selectivity relative to that of their reversible counterparts. Our strategy involves modifying a promiscuous kinase inhibitor with an electrophile to generate covalent inhibitors of c-Src. We applied this methodology to two inhibitor scaffolds that exhibit increased cellular efficacy when rendered irreversible. In addition, we have demonstrated the utility of irreversible inhibitors in studying the conformation of an important loop in kinases that can control inhibitor selectivity and cause drug resistance. Together, we have developed a general and robust framework for generating selective irreversible inhibitors from reversible, promiscuous inhibitor scaffolds.
引用
收藏
页码:1910 / 1917
页数:8
相关论文
共 37 条
[1]
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks [J].
Barf, Tjeerd ;
Kaptein, Allard .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (14) :6243-6262
[2]
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics [J].
Blair, Jimmy A. ;
Rauh, Daniel ;
Kung, Charles ;
Yun, Cai-Hong ;
Fan, Qi-Wen ;
Rode, Haridas ;
Zhang, Chao ;
Eck, Michael J. ;
Weiss, William A. ;
Shokat, Kevan M. .
NATURE CHEMICAL BIOLOGY, 2007, 3 (04) :229-238
[3]
Development of a Highly Selective c-Src Kinase Inhibitor [J].
Brandvold, Kristoffer R. ;
Steffey, Michael E. ;
Fox, Christel C. ;
Soellner, Matthew B. .
ACS CHEMICAL BIOLOGY, 2012, 7 (08) :1393-1398
[4]
Comprehensive analysis of kinase inhibitor selectivity [J].
Davis, Mindy I. ;
Hunt, Jeremy P. ;
Herrgard, Sanna ;
Ciceri, Pietro ;
Wodicka, Lisa M. ;
Pallares, Gabriel ;
Hocker, Michael ;
Treiber, Daniel K. ;
Zarrinkar, Patrick P. .
NATURE BIOTECHNOLOGY, 2011, 29 (11) :1046-U124
[5]
Dixit A., 2009, PLOS COMPUT BIOL, V5, P1
[6]
Chemical genetic strategy for targeting protein kinases based on covalent complementarity [J].
Garske, Adam L. ;
Peters, Ulf ;
Cortesi, Arianna T. ;
Perez, Jenny L. ;
Shokat, Kevan M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (37) :15046-15052
[7]
Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc [J].
Getlik, Matthaeus ;
Gruetter, Christian ;
Simard, Jeffrey R. ;
Klueter, Sabine ;
Rabiller, Matthias ;
Rode, Haridas B. ;
Robubi, Armin ;
Rauh, Daniel .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (13) :3915-3926
[8]
Understanding the Impact of the P-loop Conformation on Kinase Selectivity [J].
Guimaraes, Cristiano R. W. ;
Rai, Brajesh K. ;
Munchhof, Michael J. ;
Liu, Shenping ;
Wang, Jian ;
Bhattacharya, Samit K. ;
Buckbinder, Leonard .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2011, 51 (06) :1199-1204
[9]
FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth [J].
Hauck, CR ;
Hsia, DA ;
Puente, XS ;
Cheresh, DA ;
Schlaepfer, DD .
EMBO JOURNAL, 2002, 21 (23) :6289-6302
[10]
Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines [J].
Holbeck, Susan L. ;
Collins, Jerry M. ;
Doroshow, James H. .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) :1451-1460